Abstract:Psychedelics changes in perception through serotonin receptor agonism. Effects on the 5HT2A receptor; neuroplasticity and transcriptomic regulation, as well as specific changes in neural correlates of brain networks. Psychedelic‐assisted therapy in disorders such as depression, anxiety and substance use disorders constitutes a strong research area, thus evaluating the clinical use is highly essential (this figure was created with BioRender.com). Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N′‐dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5‐HT2A receptor activation. Lysergic acid diethylamide, the first famous breakthrough in the field, was discovered by chance by Albert Hoffman in the Zurich Sandoz laboratory in 1943, and studies on its psychoactive effects began to take place in the literature. Studies in this area were blocked after the legislation controlling the use and research of psychedelic drugs came into force in 1967, but since the 1990s, it has started to be a matter of scientific curiosity again by various research groups. In particular, with the crucial reports of psychotherapy‐assisted psilocybin applications for life‐threatening cancer‐related anxiety and depression, a new avenues have been opened in the treatment of psychiatric diseases such as treatment‐resistant depression and substance addictions. An increasing number of studies show that psychedelics have a very promising potential in the treatment of neuropsychiatric diseases where the desired efficiency cannot be achieved with conventional treatment methods. In this context, we discuss psychedelic therapy, encompassing its historical development, therapeutic applications and potential treatment effects—especially in depression, trauma disorders and substance use disorders—within the framework of ethical considerations.

Beyond the numbers: reimagining healing with psychedelics for eating disorders

Psychedelics and the treatment of eating disorders: considerations for future research and practice

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

Perspectives and preliminary experiences of psychedelics for the treatment of eating disorders: A systematic scoping review

Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

Psilocybin, moralization and psychotherapy: a coping review and a case report

Psychedelics and Other Psychoplastogens for Treating Mental Illness

Psychedelic therapy in depression and substance use disorders

The cyclical revival of psychedelics in psychiatric treatment

Psychedelic research at a crossroads

Scientifically Integrating Psychedelics with Counseling: Education, Guidance, and Implications for Mental Health Practitioners

A framework for assessment of adverse events occurring in psychedelic-assisted therapies

Beyond psychedelics: set and setting in general psychiatric practice

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

A perspective on psychedelics as treatments for addictions: Past, Present, and Future

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders

Psychedelic Research and Therapeutic Practices: Embracing Communities, Groups, and Traditional Knowledge